Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Expensive Performer

1446.7500 -6.25 (-0.43%)

NSE Mar 25, 2025 15:31 PM

37.52% Gain from 52W Low

Volume: 227.6K

Ipca Laboratories Ltd.

14 Oct 2024

1446.75

-0.43%

At an inflexion point

Buy: Ipca Laboratories Ltd.

Recommendation Target

Motilal Oswal

After three years of earnings deterioration, IPCA is well-poised to deliver strong earnings growth over FY24-27.

Number of FII/FPI investors increased from 268 to 282 in Dec 2024 qtr.